NCT05954286 - PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

April 24, 2025

Study Completion Date

April 24, 2025

Conditions

SARS-CoV-2

Interventions

DRUG

Upamostat

Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.

DRUG

Placebo (PO)

Oral Capsules

Trial Locations (6)

9300

Josha Research, Bloemfontein

10400

Royal Thai Army Clinical Research Center (RTA CRC) Royal Thai Army-Armed Forces Research Institute of Medical Sciences (RTA-AFRIMS), Bangkok

21287

Johns Hopkins Hospital, Baltimore

37209

KUR Research, Nashville

44106

University Hospitals Cleveland Medical Center, Cleveland

Unknown

Makerere University Walter Reed Project, Fort Portal

All Listed Sponsors

collaborator

Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies

OTHER_GOV

collaborator

RedHill Biopharma Limited

INDUSTRY

collaborator

FHI Clinical, Inc.

UNKNOWN

lead

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER